Literature DB >> 34061606

Development and validation of a multivariable model and online decision-support calculator to aid in preoperative discrimination of benign from malignant splenic masses in dogs.

Kristine E Burgess, Lori Lyn Price, Ryan King, Manlik Kwong, Eliza Grant, Katherine A Olson, Jeremiah A Lyons, Nicholas A Robinson, Kristin M Wendelburg, John Berg.   

Abstract

OBJECTIVE: To develop a multivariable model and online decision-support calculator to aid in preoperative discrimination of benign from malignant splenic masses in dogs. ANIMALS: 522 dogs that underwent splenectomy because of splenic masses. PROCEDURES: A multivariable model was developed with preoperative clinical data obtained retrospectively from the records of 422 dogs that underwent splenectomy. Inclusion criteria were the availability of complete abdominal ultrasonographic examination images and splenic histologic slides or histology reports for review. Variables considered potentially predictive of splenic malignancy were analyzed. A receiver operating characteristic curve was created for the final multivariable model, and area under the curve was calculated. The model was externally validated with data from 100 dogs that underwent splenectomy subsequent to model development and was used to create an online calculator to estimate probability of splenic malignancy in individual dogs.
RESULTS: The final multivariable model contained 8 clinical variables used to estimate splenic malignancy probability: serum total protein concentration, presence (vs absence) of ≥ 2 nRBCs/100 WBCs, ultrasonographically assessed splenic mass diameter, number of liver nodules (0, 1, or ≥ 2), presence (vs absence) of multiple splenic masses or nodules, moderate to marked splenic mass inhomogeneity, moderate to marked abdominal effusion, and mesenteric, omental, or peritoneal nodules. Areas under the receiver operating characteristic curves for the development and validation populations were 0.80 and 0.78, respectively. CONCLUSIONS AND CLINICAL RELEVANCE: The online calculator (T-STAT.net or T-STAT.org) developed in this study can be used as an aid to estimate the probability of malignancy in dogs with splenic masses and has potential to facilitate owners' decisions regarding splenectomy.

Entities:  

Mesh:

Year:  2021        PMID: 34061606      PMCID: PMC8908434          DOI: 10.2460/javma.258.12.1362

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  43 in total

Review 1.  Acute phase proteins in dogs and cats: current knowledge and future perspectives.

Authors:  Jose Joaquýn Ceron; Peter David Eckersall; Silvia Martýnez-Subiela
Journal:  Vet Clin Pathol       Date:  2005-06       Impact factor: 1.180

2.  Canine angiosarcoma: cytologic, histologic, and immunohistochemical correlations.

Authors:  Walter Bertazzolo; Marta Dell'Orco; Ugo Bonfanti; Gabriele Ghisleni; Mario Caniatti; Carlo Masserdotti; Elisa Antoniazzi; Luca Crippa; Paola Roccabianca
Journal:  Vet Clin Pathol       Date:  2005       Impact factor: 1.180

3.  CCNU for the treatment of dogs with histiocytic sarcoma.

Authors:  Katherine A Skorupski; Craig A Clifford; Melissa C Paoloni; Ana Lara-Garcia; Lisa Barber; Michael S Kent; Amy K LeBlanc; Aarti Sabhlok; Elizabeth A Mauldin; Frances S Shofer; C Guillermo Couto; Karin U Sørenmo
Journal:  J Vet Intern Med       Date:  2007 Jan-Feb       Impact factor: 3.333

4.  Histologic and immunohistochemical review of splenic fibrohistiocytic nodules in dogs.

Authors:  A S Moore; A E Frimberger; N Sullivan; P F Moore
Journal:  J Vet Intern Med       Date:  2012-08-07       Impact factor: 3.333

5.  Prevalence of hemangiosarcoma in anemic dogs with a splenic mass and hemoperitoneum requiring a transfusion: 71 cases (2003-2005).

Authors:  Tara N Hammond; S Anna Pesillo-Crosby
Journal:  J Am Vet Med Assoc       Date:  2008-02-15       Impact factor: 1.936

6.  Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma.

Authors:  Karin U Sorenmo; Jennifer L Baez; Craig A Clifford; Elizabeth Mauldin; Beth Overley; Katherine Skorupski; Roxanne Bachman; Marissa Samluk; Frances Shofer
Journal:  J Vet Intern Med       Date:  2004 Mar-Apr       Impact factor: 3.333

7.  Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases (1997-2004).

Authors:  Stanley E Kim; Julius M Liptak; Trent T Gall; Gabrielle J Monteith; J Paul Woods
Journal:  J Am Vet Med Assoc       Date:  2007-11-15       Impact factor: 1.936

8.  Splenomegaly in dogs. Predictors of neoplasia and survival after splenectomy.

Authors:  K A Johnson; B E Powers; S J Withrow; M J Sheetz; C R Curtis; R H Wrigley
Journal:  J Vet Intern Med       Date:  1989 Jul-Sep       Impact factor: 3.333

9.  Prognosis for acute nontraumatic hemoperitoneum in the dog: a retrospective analysis of 60 cases (2003-2006).

Authors:  Michael G Aronsohn; Beata Dubiel; Brian Roberts; Barbara E Powers
Journal:  J Am Anim Hosp Assoc       Date:  2009 Mar-Apr       Impact factor: 1.023

10.  A hypertension risk score for middle-aged and older adults.

Authors:  Abhijit V Kshirsagar; Ya-Lin Chiu; Andrew S Bomback; Phyllis A August; Anthony J Viera; Romulo E Colindres; Heejung Bang
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-10       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.